




Towards comprehensive management of symptomatic endometriosis: beyond the dichotomy of medical versus surgical treatment

Velja Mijatovic ^{1,*} and Paolo Vercellini ²

¹Department of Gynaecology & Reproductive Medicine, Academic Endometriosis Center, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

²Department of Clinical Sciences and Community Health, Università degli Studi and Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy

*Correspondence address. Department of Gynaecology & Reproductive Medicine, Academic Endometriosis Center, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. E-mail: mijatovic@amsterdamumc.nl  <https://orcid.org/0000-0002-0435-9921>

ABSTRACT

Except when surgery is the only option because of organ damage, the presence of suspicious lesions, or the desire to conceive, women with endometriosis-associated pain often face a choice between medical and surgical treatment. In theory, the description of the potential benefits and potential harms of the two alternatives should be standardized, unbiased, and based on strong evidence, enabling the patient to make an informed decision. However, doctor's opinion, intellectual competing interests, local availability of specific services and (mis)information obtained from social media, and online support groups can influence the type of advice given and affect patients' choices. This is compounded by the paucity of robust data from randomized controlled trials, and the anxiety of distressed women who are eager to do anything to alleviate their disabling symptoms. Vulnerable patients are more likely to accept the suggestions of their healthcare provider, which can lead to unbalanced and physician-centred decisions, whether in favour of either medical or surgical treatment. In general, treatments should be symptom-orientated rather than lesion-orientated. Medical and surgical modalities appear to be similarly effective in reducing pain symptoms, with medications generally more successful for severe dysmenorrhoea and surgery more successful for severe deep dyspareunia caused by fibrotic lesions infiltrating the posterior compartment. Oestrogen–progestogen combinations and progestogen monotherapies are generally safe and well tolerated, provided there are no major contraindications. About three-quarters of patients with superficial peritoneal and ovarian endometriosis and two-thirds of those with infiltrating fibrotic lesions are ultimately satisfied with their medical treatment although the remainder may experience side effects, which may result in non-compliance. Surgery for superficial and ovarian endometriosis is usually safe. When fibrotic infiltrating lesions are present, morbidity varies greatly depending on the skill of the individual surgeon, the need for advanced procedures, such as bowel resection and ureteral reimplantation, and the availability of expert colorectal surgeons and urologists working together in a multidisciplinary approach. The generalizability of published results is adequate for medical treatment but very limited for surgery. Moreover, on the one hand, hormonal drugs induce disease remission but do not cure endometriosis, and symptom relapse is expected when the drugs are discontinued; on the other hand, the same drugs should be used after lesion excision, which also does not cure endometriosis, to prevent an overall cumulative symptom and lesion recurrence rate of 10% per postoperative year. Therefore, the real choice may not be between medical treatment and surgery, but between medical treatment alone and surgery plus postoperative medical treatment. The experience of pain in women with endometriosis is a complex phenomenon that is not exclusively based on nociception, although the role of peripheral and central sensitization is not fully understood. In addition, trauma, and especially sexual trauma, and pelvic floor disorders can cause or contribute to symptoms in many individuals with chronic pelvic pain, and healthcare providers should never take for granted that diagnosed or suspected endometriosis is always the real, or the sole, origin of the referred complaints. Alternative treatment modalities are available that can help address most of the additional causes contributing to symptoms. Pain management in women with endometriosis may be more than a choice between medical and surgical treatment and may require comprehensive care by a multidisciplinary team including psychologists, sexologists, physiotherapists, dieticians, and pain therapists. An often missing factor in successful treatment is empathy on the part of healthcare providers. Being heard and understood, receiving simple and clear explanations and honest communication about uncertainties, being invited to share medical decisions after receiving detailed and impartial information, and being reassured that a team member will be available should a major problem arise, can greatly increase trust in doctors and transform a lonely and frustrating experience into a guided and supported journey, during which coping with this chronic disease is gradually learned and eventually accepted. Within this broader scenario, patient-centred medicine is the priority, and whether or when to resort to surgery or choose the medical option remains the prerogative of each individual woman.

Keywords: endometriosis / pelvic pain / dysmenorrhoea / dyspareunia / medical treatment / surgery / central sensitization / infertility / self-management

Received: July 13, 2023. Revised: December 06, 2023. Editorial decision: December 12, 2023.

© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: journals.permissions@oup.com

Medical or surgical treatment for endometriosis-associated pain: on empirical versus dogmatic medicine and polarization of the scientific community

In recent decades, there has been a surprising lack of high-quality comparative effectiveness research on treatments for symptomatic endometriosis. Unfortunately, this has mirrored the paucity of useful new knowledge about the pathogenesis of the disease. In general, the lack of robust translational and clinical research is conducive to the flourishing of strong personal opinions about the best management of chronic diseases. In the field of endometriosis, this has led to the elaboration of divergent and often opposing views by several experts on the safety, efficacy, and overall role of medical and surgical treatments for women with endometriosis in different clinical conditions (Pellicer and Zupi, 2016; Vercellini et al., 2018f). Thus, polarization also appears to be flourishing in the endometriosis scientific community. An active role for medical journal editors to mitigate the potential effects of polarization has been promoted (Plough and Holm, 2015). In this regard, Earp (2015) suggested that whenever an editor perceives polarization in a submitted manuscript, one of the possible options should be to solicit a commentary or response from researchers on the 'other side'.

Here, we present counterarguments to the debate article by Canis and Guo (2023) who, in an extreme and simplified synthesis, appear to favour physical removal of endometriotic lesions as the preferred upfront approach for symptomatic patients, with the role of medical treatment limited to postoperative maintenance of surgical results by preventing recurrence. The authors claim that, despite the proven benefits, many patients avoid surgery for fear of complications, and suggest that the risk of harm from surgery is exaggerated by gynaecologists who are not sufficiently surgically skilled to deal with the technically demanding conditions typical of severe, infiltrating fibrotic endometriosis (Canis et al., 2018). They also suggest that advice may sometimes be based on data from series of centres with suboptimal surgical performance. However, hormonal treatments may also be refused or discontinued precisely because of fears of side effects and health concerns (Both et al., 2019), and it cannot be excluded that advocates of surgery may exaggerate the potential harms of pharmacological therapies for endometriosis and thus unduly influence doctors' and patients' choices. Overall, there is limited information available in order to understand why patients ultimately choose medical or surgical treatment (Leonardi et al., 2020a), and the impact of clinician counselling, although likely, cannot currently be quantified. However, when complete and unbiased information is adequately provided, and the alternative between medical therapy and surgery is presented equally, the potential harms of procedures for bowel infiltrating endometriosis have been found to be a determinant of patient preference (Metzemaekers et al., 2022).

It should be emphasized that medical treatment is not an option in several circumstances, including but not limited to the following: presence of obstructive uropathy; bowel endometriosis associated with subocclusive symptoms; ovarian cysts with dubious ultrasound appearance; presence of large endometriomas (>5 cm), especially in women over 40 years of age; women seeking pregnancy; and women refusing hormonal therapies.

As a premise, it must be remembered that endometriosis is not the unique cause of chronic pelvic pain (Yosef et al., 2016; Lamvu et al., 2021) and that other determinants, such as trauma and especially sexual trauma (Panisch and Tam, 2020; Hillcoat et al., 2023), and pelvic floor disorders (Gyang et al., 2013) may act

either independent of endometriosis (Lamvu et al., 2018; Bourdon et al., 2023) or in combination with endometriosis (Aredo et al., 2017; Harris et al., 2018; Liebermann et al., 2018) in the generation of symptoms. Avoiding tunnel vision is of paramount importance to prevent both using ineffective hormonal treatments (Cetera et al., 2023; Till et al., 2023) and undertaking needless and potentially risky surgical procedures (Mowers et al., 2016) if endometriosis, even when present, is not the real or exclusive source of pain symptoms.

The effectiveness of surgery and hormonal treatments on pain

Canis and Guo (2023) support the idea that surgically removing instead of pharmacologically suppressing endometriotic lesions is in the best patient interest. Unfortunately, data from randomized controlled trials (RCTs) comparing hormone therapy and surgery for different pain symptoms are not available. In any case, treatments should be symptom-oriented rather than lesion-oriented. This is important because different treatments may provide different levels of relief depending on main pain complaint. For example, the most effective treatment for severe dysmenorrhoea appears to be menstrual suppression through continuous use of combined oral contraceptives (COCs) or progestogens. On the other hand, when severe dyspareunia limiting sexual function is associated with the presence of infiltrating and fibrotic lesions of the pouch of Douglas, the uterosacral ligaments and the posterior vaginal fornix, radical surgical excision is a reasonable option.

Some concepts should be clarified to optimize the counselling process. As Canis and Guo (2023) themselves point out, hormonal therapies control but do not eliminate ectopic endometrial foci, regardless of the magnitude of the effect. Therefore, at least from the time of non-surgical diagnosis to the time of trying to conceive, a pharmacological choice may imply several years of treatment. For a young woman, this can easily mean a decade of ovarian suppression. It makes no clinical sense to plan a few months of treatment in the expectation that symptom relief will continue despite discontinuation. Endometriosis is a chronic inflammatory disease and, as such, if drugs are chosen over surgery they should be continued indefinitely, no different from what is usually expected and done with any other chronic inflammatory disease. The reappearance of pain on discontinuation of medications is predictable and is not evidence of failure of medical treatment, simply because medications do not eliminate endometriosis, which immediately resumes its metabolic activity once ovarian function and oestradiol synthesis have resumed. The effect of hormone therapy is to induce disease remission, and relapse of symptoms is the rule when medications are stopped for any reason.

Jensen et al. (2018), based on the results of a systematic review of the effects of COCs in women with symptomatic endometriosis, concluded. "combined and progestin-only hormonal contraception present affordable and effective treatment options for women with endometriosis. Our review supports that these methods reduce menstrual and nonmenstrual pain and improve quality of life. Continuous use may result in amenorrhea and further improve outcomes compared with cyclic use. Overall, the available literature is limited, but a consistency of effect is observed supporting these recommendations".

Grandi et al. (2019) confirmed that COCs and progestogens are effective in relieving endometriosis-associated menstrual and pelvic pain and dyspareunia, thereby improving quality of life (QoL). As expected, Muzii et al. (2016) found that COCs used

continuously were more effective in reducing postoperative dysmenorrhoea recurrence rates than COCs used cyclically (risk ratio (RR), 0.24; 95% CI, 0.06–0.91). The between-group differences observed for dyspareunia and nonmenstrual pain recurrence rates were not statistically significant.

According to the results of the systematic review by Mitchell et al. (2022), progestogens significantly improved endometriosis-associated pain symptoms during 6–12 months of treatment without substantial differences between progestogen types. The median discontinuation rate owing to side effects was 0.3% (range, 0–37%), with only mild events reported. These findings are consistent with the position of Canis and Guo (2023), who affirm that progestogens are poorly tolerated also because of an increased risk of depression and significant weight gain. Canis and Guo (2023) maintain that ‘there is a tendency to one-size-fits-all treating [medically] all patients with endometriosis as if they were made from the same mould irrespective of age or their pain individually’. However, different medical interventions have been suggested, distinguishing between different pain symptoms and different disease forms, and a three-tiered risk stratification system and a stepwise pharmacological approach have been proposed for individualized treatment (Vercellini et al., 2016). Indeed, three-quarters of women with superficial peritoneal and ovarian endometriosis and two-thirds of those with infiltrating, fibrotic lesions are satisfied with their medical treatment (Vercellini et al., 2017, 2018b), including patients with non-subocclusive colorectal disease (Vercellini et al., 2018a, 2021).

When considering the use of hormonal treatments for endometriosis, the type and completeness of information provided regarding probable side effects and how to deal with them is crucial to ensure optimal acceptability, and thus effectiveness. In fact, in a cross-sectional study among more than 3000 endometriosis patients conducted via the most popular social media channels, potential side effects affecting mental health was the most important reason for refusing endocrine therapies. At the same time, a considerable proportion of subjects reported having limited knowledge about these medications and indicated that social media were their most useful source of information (Thurnherr et al., 2023). These findings further emphasize the importance of adequate counselling to prevent misunderstanding and potentially increase adherence. Obviously, the same applies to surgical treatment.

Canis and Guo (2023) maintain that ‘the effectiveness of surgery in the treatment of pain has been demonstrated in several double-blinded, randomized clinical trials’, but cite two old small studies only. Sutton et al. (1994) recruited 63 symptomatic patients with minimal to moderate endometriosis and observed pain improvement or resolution at 6-month follow-up in less than two-thirds of subjects allocated to laparoscopic laser ablation of lesions and uterosacral nerves, and in almost one-quarter of those allocated to diagnostic laparoscopy. Abbott et al. (2004) randomized a selected group of 39 patients with minimal to severe endometriosis to lesion excision or diagnostic-only laparoscopy. Six months after the procedure, symptoms improved in four-fifths of the participants in the surgical treatment group and in almost one-third of those in the no-treatment group. Although we agree that conducting such type of trials is challenging, we also consider that more high-quality data are needed to define the effect of surgery on endometriosis-associated pain in different clinical conditions. Leonardi et al. (2020a) reviewed the published controlled trials on the effectiveness of surgery for endometriosis-associated pain and found a significant overall difference between operative and diagnostic laparoscopy (RR, 2.65; 95% CI, 1.61–4.34). However, the specific

effect on dysmenorrhoea, dyspareunia, and dyschesia was inconsistent among the considered studies, and there were limited data on the long-term effect of surgery *per se*. When surgery is combined with postoperative medical treatment, it is not possible to distinguish between the effects of the two interventions separately. There was not enough evidence to assess the impact on disease progression. This does not rule out a benefit from surgery.

Destruction of superficial peritoneal endometriosis in women with chronic pelvic pain has been criticized and its effect questioned (Horne et al., 2019), and multicentre RCTs (ESPrIT1 and ESPrIT2) are underway to assess the clinical and cost-effectiveness of this treatment modality (Whitaker et al., 2021; Mackenzie et al., 2023).

In women with ovarian and infiltrating fibrotic endometriosis, numerous uncontrolled, mostly retrospective studies report favourable outcomes of surgery for all types of pain, in all types of advanced anatomic conditions, and with all types of instrumentation, including laser- and robot-assisted surgery. However, without the support of randomized data, it is impossible to assess whether drugs or surgery should be chosen for pain relief in different clinical conditions. Although the effectiveness of correctly performed surgery for pain relief in women with moderate to severe endometriosis is evident in everyday practice, it cannot be precisely quantified and compared with medical therapies because of major biases inherent in the available studies, including a very high likelihood of publication bias (who is willing to submit bad results that compare unfavourably with the available evidence?). Overall, almost one-third of patients who undergo surgery for endometriosis-associated pain do not benefit from the procedure, and no predictors of response to treatment have been identified (Ball et al., 2021). It is also unclear what proportion of patients experience only partial or temporary pain relief.

It cannot be excluded that most of the available results, both medical and surgical, are influenced by patient self-selection and therefore may not be generalizable to women who have not chosen their preferred treatment modality. Currently, women who have already been diagnosed with endometriosis tend to seek information on the internet and from peers through patient organizations. As a result, many patients self-select their favoured referral centre based on their priorities, preferences, or previous experience. Women who are dissatisfied with medical therapies because they are ineffective or intolerable or who are unwilling to take hormones for long periods of time, tend to choose centres of expertise known for their excellent surgical profile, whereas those who prefer to avoid surgery or who have already undergone unsuccessful procedures tend to choose centres known for their extensive experience with pharmacological therapies. From a methodological point of view, when assessing this type of evidence, it is important to remember that the reported findings apply only to those women who have deliberately chosen their preferred treatment modality. However, many women do not have the opportunity to self-select their referral centre and are designated to consult community gynaecologists without specific expertise. Also, there are many centres that have established a good balance between medical and surgical therapy for endometriosis.

The safety of surgery in women with superficial peritoneal implants, ovarian endometriomas, and infiltrating fibrotic endometriosis

Superficial peritoneal endometriosis is a surgically low-risk condition that can be treated by most gynaecologists. Ovarian

endometriomas could be considered moderate-risk lesions that can be safely managed outside centres of excellence, provided the surgeon is aware of the potential damage to ovarian reserve and applies microsurgical principles (Canis et al., 2003; Matsuzaki et al., 2009; Bourdel et al., 2020). Infiltrating fibrotic lesions may instead be classified as high-risk lesions if the bowel and ureters are involved and opening of the intestinal lumen is required to achieve radicality (Kondo et al., 2011).

According to Canis and Guo (2023), 'the risk of complications from surgery could be exaggerated out of proportion', and 'the patient's fear of transient colostomy and the surgeon's fear of litigation are likely driving the no surgery decision'. However, Bendifallah et al. (2021) reported the results of a systematic review of surgical outcomes of colorectal surgery for endometriosis. The mean complication rate after rectal shaving, disc excision, and segmental resection was 2.2%, 9.7%, and 9.9% respectively. Complications included bowel leakage, rectovaginal fistula formation, voiding dysfunction, and anastomotic stenosis. According to the authors, 'colorectal surgery exposes patients to a risk of severe complications'. Rectal shaving appears to be less risky but is not feasible in all women with extensive bowel infiltration.

In addition, the results of an exceptionally large series of 1102 women who underwent surgery for infiltrating rectosigmoid endometriosis were published by Roman et al. (2020). A total of 23 patients developed a rectovaginal fistula and 14 presented with bowel leakage. Almost half of these women ($n=11$) required more than one additional procedure to repair the rectovaginal fistula. The authors concluded that laparoscopic treatment of rectosigmoid endometriosis is associated with a relatively low risk of bowel fistula. Yet, except in the presence of clearly subocclusive lesions, whether a 3.4% risk of bowel fistula is high or low should probably be determined by the woman rather than the physician, especially when conservative alternatives are available (Vercellini et al., 2018a, 2021). The same research group published the results of a series of 363 women who underwent concomitant vaginal and rectal excision for rectovaginal endometriotic plaques (Roman et al., 2022). A rectovaginal fistula developed in 31 patients (8.5%) regardless of performance of a protective stoma. The risk was more than tripled if the rectal suture was placed within 8 cm of the anal verge.

Of relevance is that the above percentages were observed when the procedures were performed by unusually talented surgeons with probably the most experience in bowel surgery for endometriosis in the world. Obviously, these results cannot be generalized, and it cannot be assumed that the technique *per se* is associated with the reported complication rates. Although the complication rate is lower when the digestive and urinary tracts are not involved (Vallee et al., 2018), the correct information still is that the above results are to be expected only in the hands of a few super-surgeons and that both efficacy and safety may be substantially different in less favourable circumstances. Contrary to what Canis and Guo (2023) suggest, this is not meant to scare women; it is honest advice. The patient, not the surgeon, bears the burden of complications. Different women can accept different levels of risk, and they, not the physician, should decide how high to set the bar (Bretthauer and Kalager, 2023).

An international committee with representatives from patient associations and gynaecological scientific societies should develop a list of potential complications, together with percentage probabilities derived from a systematic literature review, for all surgical procedures performed in women with different forms of endometriosis. Such a document should be endorsed by major professional organizations and then published in high-impact

journals in the field. This document, which should be used as a reference for all endometriosis patients scheduled for surgery, would help to overcome incessant discussions, and could prevent medico-legal sequelae. Informing women quantitatively about the possible complications of surgery and their frequency is not optional, as generally it is a state law. Failure to do this violates the principle of patient empowerment.

The safety and tolerability of long-term combined oestrogen-progestogen therapy and progestogen monotherapy

Canis and Guo (2023) emphasize the potential harms of hormonal treatments for endometriosis, including the increase in risk of thromboembolism, myocardial infarction, stroke, meningiomas, and malignant transformation of endometriotic lesions. However, COCs and progestogens are safe, provided that guidelines and recommendations on absolute and relative contraindications are followed (Altshuler et al., 2015; Royal College of General Practitioners, 2016; Centers for Disease Control and Prevention, 2016). Extremely long-term, large, prospective cohort studies have clearly shown that former COC users are not at increased risk of death from any cause including cancer (Hannaford et al., 2010; Vessey et al., 2010). Long-term use of COC is associated with dramatic reductions in the risk of ovarian and endometrial cancers that persist for decades after hormone withdrawal. The risk of colorectal cancer is also reduced (Vessey and Yeates, 2013; Iversen et al., 2017b, 2018). Thus, also considering that the risk of breast cancer attributable to COCs is extremely low and rapidly vanishing at discontinuation, their use is associated with a favourable overall oncological balance (Hunter, 2017). After 10 years of COC use, the risk of ovarian cancer in women with endometriosis is lower than that observed in the general female population of corresponding age (Modugno et al., 2004). This is particularly important given the increased risk of ovarian cancer associated with endometriosis.

The increased risk of meningioma observed in noregestrol acetate (NOMAC) users appears to be of uncertain individual clinical significance in young women using a commercially available COC containing oestradiol valerate 1.5 mg and NOMAC 2.5 mg per tablet, as age is by far the most important risk factor (Vercellini et al., 2023b). Recently, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency reviewed the available data, including post-marketing safety data, and concluded 'that the benefits of medicines containing noregestrol or chlormadinone outweigh the risks, provided new measures are taken to minimize the risk of meningioma'. On 28 October 2022, the European Commission (EMA/H/A-31/1510) eventually informed that, 'No new safety concern regarding a risk of meningioma associated with the use of [...] low dose (2.5 mg) noregestrol acetate containing contraceptives could be identified' (European Medicine Agency, 2022). Absolute estimates of attributable risk according to strata of age and duration of use of COCs containing NOMAC have been defined to be used for patient counselling (Vercellini et al., 2023b).

Thromboembolic risk should be contextualized considering the baseline risk of the population being studied. Young women with no known additional risk factors, including a positive family history of hereditary thrombophilia, have a very low absolute risk of thromboembolic events, so even a 2- or 3-fold increase in risk may represent a marginal absolute individual risk. In addition, COCs containing natural oestradiol or estetrol, which have been shown to have a lower risk of thromboembolic events than those containing ethinyl-oestradiol (EE), could be chosen

(Klipping et al., 2021; Chen et al., 2022; Heikinheimo et al., 2022; Morimont et al., 2022). To limit both thromboembolic events and stimulation of endometriotic lesions, oestrogen–progestogen combinations with the lowest possible oestrogen content should be preferred (Oedingen et al., 2018).

The norelgestromin and EE transdermal contraceptive patch is associated with higher EE serum levels compared with a standard dose COC containing 30 µg EE (Di Meglio et al., 2018). Probably, this is the reasons for the frequently reported mastodynia and the increased venous thromboembolic risk in current users compared with other available oestrogen–progestogen contraceptive combinations (Lidegaard et al., 2012; Galzote et al., 2017; Tepper et al., 2017; Heikinheimo et al., 2022). Moreover, presumably because of the frequency of detachment, the discontinuation rate of contraceptive transdermal patches has been reported to be high particularly in young individuals, i.e. precisely those patients that may be prone to scarce treatment adherence (Powell, 2017; Lahoti et al., 2021).

An increase in venous thromboembolic risk compared with COC users has been observed for contraceptive vaginal ring users also (Lidegaard et al., 2012). Use of vaginal rings has been associated with increased vaginal discharge and frequency of vaginitis (Lopez et al., 2013). The hypothetical acceptability among non-ring users has been reported to be limited (Ridgeway et al., 2022). Moreover, frequent spotting and breakthrough bleeding have been experienced by patients using hormonal rings continuously with the intent of providing amenorrhoea (Vercellini et al., 2010). Thus, cost of therapy may increase when newly inserted rings have to be removed to allow a hormone-free interval in case of prolonged uterine bleeding (MacGregor and Guillebaud, 2018).

For the above reasons, transdermal patches and vaginal rings do not seem to qualify as the optimal first-line hormonal treatment modalities for patients with symptomatic endometriosis.

In women with endometriosis, COCs are generally used not as a contraceptive, for which there are non-pharmacological alternatives, but rather as an effective therapy for an often disabling condition, for which the alternative is to use less safe and more costly drugs or surgery. Moreover, patients with endometriosis do not appear to be at increased risk of thromboembolic events (Wiegiers et al., 2022). Women with endometriosis who smoke should be advised to stop smoking owing to their numerous negative health consequences, and this would also allow them to use COCs. In addition, oral progestogen monotherapies do not increase the risk of thromboembolism (Mantha et al., 2012).

A decision aid for women with endometriosis, developed by the National Institute for Health and Care Excellence (2017b), is available online (<https://www.nice.org.uk/guidance/ng73/resources/patient-decision-aid-hormone-treatment-for-endometriosis-symptoms-what-are-my-options-pdf-4595573197>) With this decision aid, patients can better understand the characteristics of different hormone treatments for endometriosis and visually quantify absolute increase in risk of thromboembolism and breast cancer associated with COCs according to duration of use.

Canis and Guo (2023) state that the tolerability of COCs and progestogens used continuously is limited also by the risk of insurgence of depressive symptoms, decreased libido, and frequent, unscheduled uterine bleeding. In particular, repetitive bleeding episodes would boost tissue injury and repair processes, perpetuating lesion progression and worsening pain symptoms.

We agree that irregular uterine bleeding is a common complaint of women using COCs or progestogens in continuous mode, but also believe that the frequency and severity of such episodes can be limited. The simplest way to manage these

painful and disruptive events is to discontinue hormones for 4–7 days and then restart (Vercellini et al., 2018b). Informing women about the likelihood of unexpected bleeding and how to manage it is very important to reduce anxiety and ensure adherence. Prescribing a single injection of a depot GnRH agonist before starting progestogen therapy may reduce bleeding episodes, which occur mainly in the first few months of treatment (Kitawaki et al., 2011).

Although adverse effects on mood are often cited as a reason for discontinuation of COCs, a causal relation has not been definitively established, and a large body of data published over the past 30 years support the notion that most women report unchanged or improved mood (Schaffir et al., 2016). It cannot be excluded that a proportion of women experiencing depressive symptoms have underlying mood disorders that may be manifested or exacerbated by COC use (Schaffir et al., 2016; Buggio et al., 2022). Similar considerations also appear to apply to progestogen monotherapies (Worly et al., 2018).

In this regard, the effects of hormonal medications on mood in women with endometriosis seem difficult to interpret, as depressive symptoms are more common in these patients compared to the general female population (Gambadauro et al., 2019). In addition, the overall effect of COCs and progestogens on mood should be considered in balance, taking into account the proportion of women who may experience adverse effects, but also those who may experience relief from pre-treatment depression owing to poor QoL as a result of the pain relief provided by hormones. Despite the perception of an adverse influence of COCs and progestogens on sexual function, there is a paucity of robust data from adequately designed trials. A systematic review on this topic included a total of 8422 women evaluated in 36 studies (Pastor et al., 2013). Almost two-thirds (5358; 64%) reported no change in sexual desire, 1826 (23%) reported an increase, and 1238 (15%) reported a decrease. Thus, approximately one in seven women experienced a decrease in libido while using COCs, which may have an impact on health-related QoL, especially considering the young age of most patients with endometriosis and the negative effect the disease already has on a woman's self-image, self-esteem, and self-confidence. Data from a recent prospective cohort study suggest that progestogens also, when used at high doses to treat symptomatic endometriosis, may impair some aspects of sexual function (pleasure and satisfaction with frequency of intercourse) despite their beneficial effect on deep dyspareunia (Oppenheimer et al., 2021).

Finally, according to Canis and Guo (2023), 'extended use of COCs may result in endometrial thinning that is difficult to rectify by estrogen'. However, hormonal contraception does not adversely affect fertility after discontinuation and does not delay conception (Girum and Wasie, 2018).

Prevention of recurrence of symptoms and lesions: the surgeon has no clothes

Guo (2009) reported that the postoperative recurrence rate is estimated to be over 20% at 2-year follow-up and between 40% and 50% at 5-year follow-up. This means that the probability of symptom recurrence is approximately 10% per year for the first 5 years after endometriosis surgery. Thus, Canis and Guo (2023) advocate a combined surgical-medical approach, because 'postoperative hormonal therapy reduces the risk of recurrence and is likely to maintain the systemic effect resulting from surgery', but detailed quantitative information beyond general statements is needed here.

About 15 years ago, [Seracchioli et al. \(2009\)](#), based on an analysis of the available evidence on the preventative effect of postoperative medical treatment, suggested that long-term use of COCs reduces both symptom and lesion recurrence. Twelve years later, [Zakhari et al. \(2021\)](#) observed that the use of postoperative medical treatments reduced the risk of lesion and symptom recurrence at 18-month follow-up by almost 60% (RR, 0.41; 95% CI, 0.26–0.65). The RR point estimates were 0.36 for COCs, 0.21 for the levonorgestrel-releasing IUD (LNG-IUD), 0.17 for progestogens, and 0.62 for GnRH agonists. More recently, [Chiu et al. \(2022\)](#) conducted a systematic review and network meta-analysis to assess the effect of different hormonal therapies used for more than 1 year to reduce postoperative endometrioma recurrence. The use of several considered medical interventions, including dienogest, COCs, and GnRH agonists plus COCs, or LNG-IUD, was associated with a risk reduction of between 80% and 90%.

Two recent systematic reviews are available specifically on the effect of postoperative dienogest use. [Zakhari et al. \(2020\)](#) observed an incidence of postoperative endometrioma and pain recurrence of 2 per 100 women over a mean follow-up of 29 months in women treated with dienogest compared with 29 per 100 in women managed expectantly over a mean follow-up of 36 months. [Muzii et al. \(2023\)](#) confirmed the dramatic reduction in the risk of both lesion and pain recurrence after surgery in dienogest users compared with non-users (odds ratio (OR), 0.14; 95% CI, 0.07–0.26). The effect was similar to that of GnRH agonists (OR 0.81; 95% CI, 0.18–3.65), but with a different side-effect profile.

A favourable effect of postoperative LNG-IUD insertion was demonstrated by [Song et al. \(2018\)](#). According to their meta-analysis, the risk of endometriosis recurrence was reduced by 60% (RR = 0.40, 95% CI, 0.26–0.64) in users compared with nonusers of the medicated device. The effect was similar to that of postoperative COC use, but satisfaction with treatment was higher with the LNG-IUD.

Finally, the use of postoperative medical therapy in women who do not want to conceive immediately is recommended in the latest version of the ESHRE guideline on endometriosis ([Becker et al., 2022](#)). Therefore, long-term medical treatment after surgical removal of endometriotic lesions should now be considered an essential part of disease management in all patients who are willing and able to take and tolerate hormones, as failure to do so or to provide adequate information to women means exposing them to an increased risk of re-operation, further damage to the reproductive organs, and a reduced likelihood of achieving pregnancy ([Vercellini et al., 2009a,b](#)). This has ethical and possibly medical-legal implications.

Therefore, while we agree with [Canis and Guo \(2023\)](#) that surgical treatment should always be followed by suppressive hormone therapy until conception is desired, at the same time we note that the elephant in the room here is that it is unclear why the use of oestrogen-progestogen combinations or progestogen monotherapies is discouraged as an alternative to surgery, but the use of the same drugs after surgery is recommended. In fact, all the safety and tolerability issues raised for prolonged medical treatment, including thromboembolic and oncological concerns, apply without difference regardless of the timing or sequence of use.

Alternative to colorectal surgery in infertility: IVF as comparator

[Canis and Guo \(2023\)](#) state that ART is not always an acceptable treatment for endometriosis-associated infertility as an increasing number of women are seeking a more physiological

management, i.e. natural conception after fertility-enhancing surgery. Although this may be reasonable, no evidence was provided to demonstrate this trend. Moreover, anatomical-clinical conditions vary widely in infertile patients with endometriosis, and the final choice between surgery and ART is also based on trade-offs between potential benefits and potential harms of the two options. In this regard, colorectal endometriosis appears to constitute an exemplary situation.

In general, patients with endometriosis who have bowel symptoms associated with non-occlusive colorectal endometriosis and no wish to conceive can usually be treated with medical management ([Egekvist et al., 2017](#)). The indication for colorectal surgery should be based on symptomatology (obstructive bowel complaints, severe pain which is nonresponsive to medical treatment and diminished QoL), supported by findings on abdominal imaging such as nodules larger than 3 cm, multiple nodules, luminal stenosis of the bowel, and more than 50% invasion of the bowel circumference.

However, surgery for deep colorectal endometriosis is usually complex and carries relatively high risks with an overall postoperative complication rate of 18.5% and a mortality rate of 0.03% ([Balla et al., 2018](#)).

Limited data are available on the outcomes of colorectal surgery regarding natural conception rates in infertile patients with endometriosis, although it is suggested that surgery may increase pregnancy rates, in the range from 24% to 50% ([Vercellini et al., 2012](#); [Cohen et al., 2014](#); [Iversen et al., 2017a](#)). However, these results arise from observational studies lacking control groups and showing considerable clinical heterogeneity. In addition, it is known that results from observational studies, with limited strength of evidence, may overestimate the treatment effect when compared to randomized trials. Moreover, outcomes of complex surgery are operator-dependent and published data are usually more favourable in their outcome than what may be expected in daily practice. Therefore, the reproductive outcomes from observational studies may provide guidance, however they should be interpreted with caution because of their methodological shortcomings and they should not be generalized as long as we lack randomized studies on colorectal surgery versus no surgery in infertile patients with endometriosis ([Vercellini et al., 2012](#)).

As colorectal endometriosis is usually accompanied by advanced intra-abdominal disease resulting in distortion of the pelvic anatomy and tubal dysfunction, it is not surprising that IVF may be considered as first line treatment. Consequently, IVF can be seen as a realistic treatment comparator to surgery as long as colorectal surgery has not proven to substantially improve natural conception. However, randomized trials comparing IVF to surgery are non-existent, as are trials that focus on the effect of surgery on the reproductive outcomes of IVF, as colorectal surgery is still mainly performed for pain and reduced QoL rather than for treating infertility.

When counselling patients for IVF, it should be emphasized that IVF does not increase disease progression and/or recurrence in women with deep endometriosis, which is reassuring ([Vercellini et al., 2018g](#)). However, at the same time, it should also be pointed out that surgery is not indicated to prevent progression of deep endometriosis or to lower the risk of complications associated with IVF and/or pregnancy, as evidence for the effectiveness of prophylactic surgery is absent.

Central sensitization: is surgery the answer?

Endometriosis-associated pain is considered a form of neuroinflammatory pain, which is mediated by inflammatory cytokines

that bind to receptors on sensory neurons and cause a wave of signalling kinases that induce the pain signal.

However, pain mechanisms in endometriosis should be considered as multifactorial (Coxon *et al.*, 2018). Alongside the peripheral pain contribution, it has been increasingly recognized that central sensitization (CS) may contribute to the perception of endometriosis-associated pain. This means that the central nervous system becomes hypersensitive to pain and gets involved in amplification and/or generation of endometriosis-associated pain. Beside this hyperexcitability of the central nervous system, CS may also be accompanied by comorbidities, such as cognitive impairment and mood disorders (As-Sanie *et al.*, 2016). In women with endometriosis, CS can cause chronic pelvic pain, which is disproportional to the severity of the disease and challenging to treat (Till *et al.*, 2023).

In clinical practice the validated Central Sensitization Inventory (CSI) is increasingly used as a questionnaire to assess CS symptom severity and mental health, showing a high degree of reliability and internal consistency (Scerbo *et al.*, 2018).

According to Canis and Guo (2023), surgical removal of endometriotic lesions reduces not only local but also systemic inflammation, and improves CS. However, in a recent prospective study using the CSI in a cohort of 239 patients, it was shown that patients with high CSI scores at baseline were associated with persisting pain and persisting high CSI scores at follow-up after surgery (Orr *et al.*, 2023). This means that in patients with high preoperative CSI scores surgery may contribute to the decrease of peripheral pain caused by endometriosis but that the centrally generated pain is likely to persist when compared to those with low CSI scores prior to surgery. This is in line with the findings of three recent studies showing that the risk of persistent chronic pelvic pain is higher if there is a high degree of CS preoperatively when compared to those with low degrees of CS (Bennett *et al.*, 2017; Roh *et al.*, 2018; As-Sanie *et al.*, 2021).

So, which alternatives to surgery are available in patients with endometriosis and CS? Nerve stimulation techniques appear to be a very promising new modality in treating CS although in these patients the data are very limited, and more research is needed to establish its clinical relevance (Simpson *et al.*, 2022). In patients with endometriosis, hormone treatments are recommended as an option to reduce endometriosis-associated pain (Becker *et al.*, 2022). In clinical research minor differences are seen between all hormone treatments in their ability to decrease pain.

However, the available evidence in patients with endometriosis and CS (defined as CSI > 40) shows self-reported pain that was nonresponsive to hormonal therapy in 18% of women in comparison to 6% in women with CSI < 40, which was statistically significant (Orr *et al.*, 2023). This outcome should be taken with caution as the evidence is limited to one cross sectional study. Nevertheless, this does not disqualify hormone therapy in patients with endometriosis and CS as it may still be required for suppression of cyclical worsening of endometriosis pain although its efficacy in women with high CSI should be addressed in future high-quality studies.

An innovative way to treat endometriosis-associated pain may be offered by virtual reality (VR). In the treatment of acute pain, and in particular procedural pain, VR has now proven itself as an effective method of distracting from pain. In chronic pain, the applications of VR are growing rapidly, and it appears that its effect is mainly based on improving the coping with pain and modifying the emotional response to pain. Recently, a RCT showed that the use of a single use 20-min VR treatment may

offer short term pain relief in patients with endometriosis experiencing moderate-to-severe pelvic pain when compared to a 2-dimensional digital control. Whether CS can be treated in this way has not been investigated yet.

For now, a multidisciplinary approach is advocated for treatment of CS in which pain education and cognitive behaviour therapy provide ways of learning to change maladaptive illness perceptions and to develop better coping skills, even if the actual level of pain stays the same. To treat chronic pain, cognitive behaviour therapy is most often used together with other methods of pain management including pelvic floor physiotherapy, and pharmaceutical or interventional treatments. It is important to note that there is no one-size-fits-all approach in treating CS in endometriosis. Treatment will depend on personal preferences and the underlying mechanism causing pain in that individual.

Self-management by complementary treatments

Medical and/or surgical treatments can be inadequate in the relief of symptoms or may be accompanied with side effects or surgical complications, which may adversely impact wellbeing and QoL of women with endometriosis.

Therefore, there is an increasing interest from both the patient community as well as medical professionals in seeking additional symptom relief or finding other treatment options alongside standard medical care and we agree with Canis and Guo (2023) when they state that alternative therapies so far have received scant attention. These complementary treatments include a range of self-management strategies. The need for self-management is influenced by the chronicity of complaints lacking a cure and the impact of the disease on QoL (Leonardi *et al.*, 2020b).

This brings us to question what the added value of self-management is for patients with endometriosis. In a recent cross sectional Australian study, an online survey was conducted via social media, and 484 women with a laparoscopically confirmed diagnosis of endometriosis were questioned (Armour *et al.*, 2019). This study showed that one or more forms of self-management was applied in 76% of the cases. In addition, it became clear that different self-management strategies have a favourable effect on endometriosis-associated pain, with dietary interventions ranking in the top three for pain reduction and being applied by 44% of the respondents.

Whether self-management improves QoL was studied in another Australian study using an online survey among endometriosis peer support groups, including 620 patients with laparoscopically confirmed endometriosis (O'Hara *et al.*, 2021). It was found that patients who used self-management strategies had a better QoL (measured by SF36) and were better able to manage chronic pain complaints than patients who did not. This favourable impact on QoL was confirmed in a recent survey among 211 Dutch women with endometriosis who used a dietary intervention (endometriosis diet) and showed a significantly improved QoL (Van Haaps *et al.*, 2023).

On the other hand, another Dutch study reported no impact of various diets on QoL of women with endometriosis although the majority of dietary interventions studied were able to reduce chronic endometriosis complaints (Krabbenborg *et al.*, 2021).

All in all, the scientific evidence regarding self-management and complementary treatment in endometriosis is limited. On the other hand, as pointed out by Canis and Guo (2023), by applying self-management patients gain more control over the disease,

which improves self-sustainability. In this light, it is recommended in the current ESHRE guideline to address complementary strategies and their value to wellbeing and coping with endometriosis symptoms, although one should emphasize that their efficacy and/or harm in treating endometriosis symptoms is unclear (Becker et al., 2022).

What does the woman with endometriosis need?

Canis and Guo (2023) believe that doctors may provide biased advice and inaccurate or partial information to dissuade patients from choosing surgery. However, there appears to be a lack of data on such a systematic phenomenon, whereas evidence is accumulating on the lack of empathy, limited ability to listen to and support suffering patients, and an inadequate or non-existent humanistic approach, irrespective of surgical or medical preference. Indeed, from previous research we know that around 50% of women with endometriosis are dissatisfied with the care they receive (Lukas et al., 2018). They often feel that they are not well informed, that they are not taken seriously and that they do not receive proper support to deal with their endometriosis-associated complaints. Therefore, it is important to focus on patient centeredness in endometriosis care, aiming to understand the needs and preferences of women with endometriosis in order to increase their coping with the disease as well as to improve compliance to treatment.

Patient-centred care is care that takes into account the preferences and aspirations of individual health care users as well as the cultures of their communities (World Health Organisation, 2006). The quality of the endometriosis care centre can be addressed by using the ENDOCARE questionnaire (ECQ), which is reliable in measuring patient centeredness. The ECQ enables a participating endometriosis care centre to identify targets of improvement and to benchmark itself with other clinics (Dancet et al., 2012; Schreurs et al., 2020a), as well as to assist in tailoring endometriosis care to individual patients (Schreurs et al., 2020b).

A person-centred approach in endometriosis care is associated with a greater feeling of control over endometriosis and more positive experiences regarding the healthcare providers involved. This is in line with a recent adequately powered study identifying relations between experiencing less patient centeredness and having a poorer QoL in patients with endometriosis (Schreurs et al., 2023). Therefore, it is plausible that improving patient centeredness may result in better QoL in women with endometriosis (Schreurs et al., 2021).

The perspective of public health authorities: the concept of 'value' and incremental benefit of medical interventions

Canis and Guo (2023) only briefly mentioned the issue of the financial burden of some hormonal drugs and the lack of cost-benefit analyses of surgical versus medical treatment of endometriosis. We believe that this aspect should be expanded, also considering the prevalence of the disease, in the interest of both patients with endometriosis and the community at large.

In 2017, the National Institute for Clinical and Health Care Excellence published the only guideline (National Institute for Health and Care Excellence, 2017a) that, based on a thorough appraisal of the available evidence with systematic reviews and network meta-analyses, not only addressed the aspect of clinical benefits and harms of several diagnostic and treatment

modalities in different clinical conditions, but also considered the individual and community economic benefits and harms of interventions with the calculation of absolute savings and additional costs, and cost-effectiveness analyses (<https://www.nice.org.uk/guidance/ng73/evidence/full-guideline-pdf-4550371315>; accessed on 30 June 2023). Thus, not only efficacy (therapeutic effect under ideal or controlled conditions) and clinical effectiveness (therapeutic effect in unselected patients in everyday practice) were considered but also efficiency, i.e. whether the input to output ratio is favourable or, in other words, whether a medical intervention is worth its cost to the individuals or society (Haynes, 1999; Burches and Burches, 2020).

Indeed, the most clinically effective treatment based on data may not be the most cost-effective option. No public health system, even in high-income countries, can afford to provide every type of health care to the entire population, regardless of cost. This introduces the concept of 'value', which is the relation between the potential benefits, potential harms, and costs of any medical intervention, including those used in the endometriosis field (Vercellini et al., 2015). According to Pandya (2018), 'to ignore health care costs implies society would pay any amount of money for services that improve the health of patients even if those services result in patients achieving only marginal improvement in health outcomes'. For example, GnRH agonists and antagonists are probably the most effective hormones for relieving endometriosis-associated pain and can be safely used for long periods when combined with add-back therapy (Yan et al., 2022; Veth et al., 2023; Xin et al., 2023). However, their cost may limit adherence or even prevent their use if individual patients have to pay for the medication. According to a recent report from the National Center for Health Statistics in 2021, 8% of US adults did not take their medications as prescribed because of cost. Women and black people were more likely to forgo therapies to reduce costs (Mykyta and Cohen, 2023; <https://www.cdc.gov/nchs/data/databriefs/db470.pdf>; accessed on 30 June 2023). Harris (2023) emphasized that 'to save money, people reported skipping doses of their medication, taking less of their drugs than prescribed, or delaying prescription refills'.

Even if public health systems reimburse the costs of taking GnRH agonists and antagonists for endometriosis, the opportunity cost should be carefully considered, as the resources consumed for expensive drugs will no longer be available for other patients with endometriosis, or for patients with other diseases, or for health services in general (Vercellini et al., 2018d,e). This may exacerbate healthcare inequalities. Therefore, a stepwise approach should be promoted, prescribing GnRH analogues only when COCs and progestogen monotherapies are ineffective, not tolerated, or contraindicated (Vercellini et al., 2015, 2018c; ETIC Endometriosis Treatment Italian Club, 2019).

Pandya (2018) asserts that 'substantial changes in price could be all that is needed to convert a low-value health care service (cost ineffective) to a high-value health care service (cost-effective)'. This occurred with a reduction in the price of dienogest to one-fifth to one-sixth of the original amount when the generic drug was marketed in Europe. A less impressive cost reduction (–25% to –30%) can still be achieved by using depot triptorelin formulations with extended-interval dosing regimens (Vercellini et al., 2023a).

Similar considerations apply to surgery for endometriosis, especially when performed robot-assisted (ETIC Endometriosis Treatment Italian Club, 2019). In any case, surgery is costly and consumes large amounts of healthcare resources. When comparing the effects of surgical and medical treatment for endometriosis-associated pain, cost-effectiveness analyses should also be conducted to weigh the trade-offs between health

outcomes and costs. Ignoring the cost of surgery for endometriosis-associated pain implies that the community would pay any amount for an incremental benefit, if any, over pharmacological interventions that are currently difficult, if not impossible, to quantify. Furthermore, in countries without public health support, the fee-for-service reimbursement model, which may encourage surgical overtreatment, should be replaced by value-based payment (ACOG Committee, 2018).

Health authorities and clinicians may have different perspectives, as medical decision-makers must ensure global equity and inclusivity, providing the greatest amount of health to the greatest number of citizens, consuming the least amount of resources, and regardless of specific diseases. High-quality surgical services may not be available everywhere, especially in low- and middle-income countries. According to Leonardi *et al.* (2020a), the setting in which care is provided is relevant to treatment decisions, as it includes the accessibility and cost of health care. In countries with inadequate health care resources, would it be better to offer surgery for endometriosis to a few patients or to relieve the pain of many with low-cost progestogens?

Conclusions: rethinking the approach to women with endometriosis-associated pain

In light of the above considerations, should we not shift from a lesion-orientated to a patient-centred approach? An approach in which a personalized treatment plan acknowledges a patient's preferences and specific endometriosis symptoms with a vision for the long term and guided by a dedicated team with knowledge and skills of endometriosis, reproductive medicine and pain management.

Assuming disease progression in at least 30% of individuals, it is conceivable that early diagnosis of endometriosis may also be associated with less extensive disease spread and thus possibly better clinical outcomes and less requirement of surgical treatment and assisted reproduction. Therefore, it is conceivable that an early diagnosis, ideally followed by early, adequate treatment, will reduce the risk of chronic pelvic pain complaints and infertility as well as provide patients with an explanation for their symptoms. A lesion-orientated surgical treatment is effective in a multitude of situations and should be applied in patients with a high severity of symptoms and low QoL where medical treatment has failed or is associated with a high burden of side effects. However, it has become clear that it should be embedded in a patient-centred approach.

Within the framework of this type of care, other causes of pain, in addition to the endometriotic lesions, should never be overlooked (Yosef *et al.*, 2016; Lamvu *et al.*, 2021), as the available evidence suggests that a large proportion of women with chronic pelvic pain have pelvic floor involvement, either primary or secondary (Aredo *et al.*, 2017; Lamvu *et al.*, 2018; Kadah *et al.*, 2023), and report a history of sexual abuse (Latthe *et al.*, 2006; Harris *et al.*, 2018; Liebermann *et al.*, 2018; Panisch and Tam, 2020; Bourdon *et al.*, 2023; Hillcoat *et al.*, 2023). Thus, in some cases, endometriosis *per se* may be asymptomatic, being an incidental finding in patients with symptoms caused by something else. We appear to have gone from a time when endometriosis was inadequately considered to one where, for some, it seems to be almost the only cause of chronic pelvic pain symptoms, an approach that does not serve patients and our healthcare systems well.

Canis and Guo (2023) argue that surgery for endometriosis-associated pain should be considered as an upfront option, rather than being indicated only when medical treatments fail.

However, in patient-centred medicine based on genuine shared decision-making, the focus may not be on whether medical or surgical treatment offers the best outcomes *a priori*, but when, under what conditions, and sometimes in what order, one of the two treatment alternatives should be used. Guidelines provide 'recommendations' that are not intended to be rigidly applied, but rather to serve as a basis for impartial information and counselling (Thornton, 2009; Bretthauer and Kalager, 2023; Howick and Doshi, 2023). If patients are uncertain, it should be assumed that the two options have different clinical implications, as those who try medical treatment and are not satisfied may then choose surgery without major consequences once hormones prove ineffective or intolerable, whereas the reverse means accepting morbidity and the risk of potential surgical harm anyway.

The success of therapy should be measured by patient-reported outcomes, such as satisfaction with treatment (Dworkin *et al.*, 2005). Women who are uncertain about the choice between medications and surgery should be offered the option to try the reversible alternative first, with a plan to reassess their clinical condition in 3–6 months. Patients who are not satisfied with the overall effect of medical treatment can then decide whether they think surgery is worthwhile, knowing that the best results are generally achieved with postoperative medical therapies anyway. An individual patient may not be completely relieved of pain symptoms or completely free of side effects, but still prefer to continue taking medications because her health-related QoL has improved sufficiently. No drug is free of side effects; the issue is the acceptable trade-off between benefit and tolerability, as this influences compliance and, ultimately, effectiveness.

Finally, experts and key opinion leaders should ultimately aim to overcome polarization in a responsible way, as it can be detrimental to women with endometriosis, who may feel confused when seeking a second or third opinion and find it difficult to make an informed decision about which treatment alternative to choose. Polarization can potentially hamper women's empowerment, interfere with shared medical decision-making, and favour doctor-centred rather than patient-centred medicine. It cannot be ruled out that women with endometriosis will eventually pay the price for our debates, which unfortunately rarely lead to a consensus that translates into major changes in individual gynaecologists' practice. The fact that this debate is taking place only 1 year after publication of the new ESHRE guideline on the diagnosis and management of endometriosis (Becker *et al.*, 2022) could be seen as indirect evidence that the polarization in our scientific community is far from being resolved.

Authors' roles

Both authors contributed equally in drafting and writing the manuscript as well as revising it twice. Both authors critically read and approved the final version of the manuscript.

Funding

No funding was received for the writing of this paper.

Conflict of interest

P.V. serves as Associate Editor for *Human Reproduction*; is a member of the Editorial Board of the *Journal of Obstetrics and Gynaecology Canada*, of the *Italian Journal of Obstetrics and Gynaecology*, and of the International Editorial Board of *Acta*

Obstetricia et Gynecologica Scandinavica; has received royalties from Wolters Kluwer for chapters on endometriosis management in the clinical decision support resource UpToDate; and maintains both a public and private gynaecological practice. V.M. reports receiving travel and speaker's fees from Guerbet, and research grants from Guerbet, Merck, and Ferring outside the scope of this work.

References

- Abbott J, Hawe J, Hunter D, Holmes M, Finn P, Garry R. Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial. *Fertil Steril* 2004;**82**:878–884.
- ACOG Committee. Opinion No. 744: value-based payments in obstetrics and gynecology. *Obstet Gynecol* 2018;**132**:e53–e59.
- Altshuler A, Gaffield ME, Kiarie JN. The WHO's medical eligibility criteria for contraceptive use: 20 years of global guidance. *Curr Opin Obstet Gynecol* 2015;**27**:451–459.
- Aredo JV, Heyrana KJ, Karp BI, Shah JP, Stratton P. Relating chronic pelvic pain and endometriosis to signs of sensitization and myofascial pain and dysfunction. *Semin Reprod Med* 2017;**35**:88–97.
- Armour M, Sinclair J, Chalmers KJ, Smith CA. Self-management strategies amongst Australian women with endometriosis: a national online survey. *BMC Complement Altern Med* 2019;**19**:17.
- As-Sanie S, Kim J, Schmidt-Wilcke T, Sundgren PC, Clau DJ, Napadow V, Harris RE. Functional connectivity is associated with altered brain chemistry in women with endometriosis-associated chronic pelvic pain. *J Pain* 2016;**17**:1–13.
- As-Sanie S, Till SR, Schrepf AD, Griffith KC, Tsodikov A, Missmer SA, Clauw DJ, Brummett CM. Incidence and predictors of persistent pelvic pain following hysterectomy in women with chronic pelvic pain. *Am J Obstet Gynecol* 2021;**225**:568.e1–568.e11.
- Ball E, Karavandra B, Kremer-Yeatman BJ, Mustard C, Lee KM, Bhogal S, Dodds J, Horne AW, Allotey J, Rivas C. Systematic review of patient-specific pre-operative predictors of pain improvement to endometriosis surgery. *Reprod Fertil* 2021;**2**:69–80.
- Balla A, Quaresima S, Subiela JD, Shalaby M, Petrella G, Sileri P. Outcomes after rectosigmoid resection for endometriosis: a systematic literature review. *Int J Colorectal Dis* 2018;**33**:835–847.
- Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, King K, Kvaskoff M, Nap A, Petersen K et al.; ESHRE Endometriosis Guideline Group. ESHRE guideline: endometriosis. *Hum Reprod Open* 2022;**2022**:hoac009.
- Bendifallah S, Puchar A, Vesale E, Moawad G, Daraï E, Roman H. Surgical outcomes after colorectal surgery for endometriosis: a systematic review and meta-analysis. *J Minim Invasive Gynecol* 2021;**28**:453–466.
- Bennett EE, Walsh KM, Thompson NR, Krishnaney AA. Central Sensitization Inventory as a predictor of worse quality of life measures and increased length of stay following spinal fusion. *World Neurosurg* 2017;**104**:594–600.
- Both S, Lew-Starowicz M, Luria M, Sartorius G, Maseroli E, Tripodi F, Lowenstein L, Nappi RE, Corona G, Reisman Y et al. Hormonal contraception and female sexuality: position statements from the European Society of Sexual Medicine (ESSM). *J Sex Med* 2019;**16**:1681–1695.
- Bourdel N, Paracchini S, Chauvet P, Fava V, Gałczyński K, Canis M. Surgical technique for endometrioma in 10 steps. *J Minim Invasive Gynecol* 2020;**27**:260–261.
- Bourdon M, Antoine V, Combes U, Maitrot-Mantelet L, Marcellin L, Maignien C, Chapron C, Santulli P. Severe pelvic pain is associated with sexual abuse experienced during childhood and/or adolescence irrespective of the presence of endometriosis. *Hum Reprod* 2023;**38**:1499–1508.
- Bretthauer M, Kalager M. What is my risk, doctor? How to convey disease risk and treatment effects. *BMJ* 2023;**381**:e075289.
- Buggio L, Barbara G, Facchin F, Ghezzi L, Dridi D, Vercellini P. The influence of hormonal contraception on depression and female sexuality: a narrative review of the literature. *Gynecol Endocrinol* 2022;**38**:193–201.
- Burches E, Burches M. Efficacy, effectiveness and efficiency in the health care: the need for an agreement to clarify its meaning. *Int Arch Public Health Community Med* 2020;**4**:035.
- Canis M, Bourdel N, Chauvet P. Endometriosis: frightening the patients is not an acceptable alternative to inadequate surgical management and or pathophysiology ignorance. *Fertil Steril* 2018;**109**:1012–1013.
- Canis M, Guo SW. In the thicket of fears, doubts, and murky facts: some reflections on treatment modalities for endometriosis-associated pain. *Hum Reprod* 2023;**38**:1245–1252.
- Canis M, Mage G, Wattiez A, Pouly JL, Bruhat MA. The ovarian endometrioma: why is it so poorly managed? Laparoscopic treatment of large ovarian endometrioma: why such a long learning curve? *Hum Reprod* 2003;**18**:5–7.
- Centers for Disease Control and Prevention. US Medical Eligibility Criteria for Contraceptive Use, 2016 (US MEC). 2016. <https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/summary.html> (29 June 2023, date last accessed).
- Cetera GE, Merli CEM, Facchin F, Viganò P, Pesce E, Caprara F, Vercellini P. Non-response to first-line hormonal treatment for symptomatic endometriosis: overcoming tunnel vision. A Narrative Review. *BMC Womens Health* 2023;**23**:347.
- Chen MJ, Jensen JT, Kaunitz AM, Achilles SL, Zatik J, Weyers S, Piltonen T, Suturina L, Apolikhina I, Bouchard C et al. Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials. *Contraception* 2022;**116**:44–50.
- Chiu CC, Hsu TF, Jiang LY, Chan IS, Shih YC, Chang YH, Wang PH, Chen YJ. Maintenance therapy for preventing endometrioma recurrence after endometriosis resection surgery—a systematic review and network meta-analysis. *J Minim Invasive Gynecol* 2022;**29**:602–612.
- Cohen J, Thomin A, Mathieu D'Argent E, Laas E, Canlorbe G, Zilberman S, Belghiti J, Thomassin-Naggara I, Bazot M, Ballester M et al. Fertility before and after surgery for deep infiltrating endometriosis with and without bowel involvement: a literature review. *Minerva Ginecol* 2014;**66**:575–587.
- Coxon L, Horne AW, Vincent K. Pathophysiology of endometriosis-associated pain: a review of pelvic and central nervous system mechanisms. *Best Pract Res Clin Obstet Gynaecol* 2018;**51**:53–67.
- Dancet EA, Apers S, Kluivers KB, Kremer JA, Sermeus W, Devriendt C, Nelen WL, D'Hooghe TM. The ENDOCARE questionnaire guides European endometriosis clinics to improve the patient-centeredness of their care. *Hum Reprod* 2012;**27**:3168–3178.
- Di Meglio G, Crowther C, Simms J. Contractive care for Canadian youth. *Paediatr Child Health* 2018;**23**:271–277.
- Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N et al.; IMMPACT. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. *Pain* 2005;**113**:9–19.
- Earp BD. Addressing polarisation in science. *J Med Ethics* 2015;**41**:782–784.
- Egekvist AG, Marinovskij E, Forman A, Kesmodel US, Riiskjaer M, Seyer-Hansen M. Conservative approach to rectosigmoid endometriosis: a cohort study. *Acta Obstet Gynecol Scand* 2017;**96**:745–750.

- ETIC Endometriosis Treatment Italian Club. When more is not better: 10 'don'ts' in endometriosis management. An ETIC position statement. *Hum Reprod Open* 2019;**2019**:hoz009.
- European Medicines Agency. Nomegestrol and Chlormadinone. 2022. <https://www.ema.europa.eu/en/medicines/human/referrals/nomegestrol-chlormadinone> (27 November 2022, date last accessed).
- Galzote RM, Rafie S, Teal R, Mody SK. Transdermal delivery of combined hormonal contraception: a review of the current literature. *Int J Womens Health* 2017;**9**:315–321.
- Gambadauro P, Carli V, Hadlaczky G. Depressive symptoms among women with endometriosis: a systematic review and meta-analysis. *Am J Obstet Gynecol* 2019;**220**:230–241.
- Girum T, Wasie A. Return of fertility after discontinuation of contraception: a systematic review and meta-analysis. *Contracept Reprod Med* 2018;**3**:9.
- Grandi G, Barra F, Ferrero S, Sileo FG, Bertucci E, Napolitano A, Facchinetti F. Hormonal contraception in women with endometriosis: a systematic review. *Eur J Contracept Reprod Health Care* 2019;**24**:61–70.
- Guo SW. Recurrence of endometriosis and its control. *Hum Reprod Update* 2009;**15**:441–461.
- Gyang A, Hartman M, Lamvu G. Musculoskeletal causes of chronic pelvic pain: what a gynecologist should know. *Obstet Gynecol* 2013;**121**:645–650.
- Hannafor PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. *BMJ* 2010;**340**:c927.
- Harris E. Survey: millions of people in the US Forgo Medications to reduce costs. *JAMA* 2023;**330**:13.
- Harris HR, Wieser F, Vitonis AF, Rich-Edwards J, Boynton-Jarrett R, Bertone-Johnson ER, Missmer SA. Early life abuse and risk of endometriosis. *Hum Reprod* 2018;**33**:1657–1668.
- Haynes B. Can it work? Does it work? Is it worth it? *Br Med J* 1999;**319**:652–653.
- Heikinheimo O, Toffol E, Partonen T, But A, Latvala A, Haukka J. Systemic hormonal contraception and risk of venous thromboembolism. *Acta Obstet Gynecol Scand* 2022;**101**:846–855.
- Hillcoat A, Prakash J, Martin L, Zhang Y, Rosa G, Tiemeier H, Torres N, Mustieles V, Adams CD, Messerlian C. Trauma and female reproductive health across the lifecourse: motivating a research agenda for the future of women's health. *Hum Reprod* 2023;**38**:1429–1444.
- Horne AW, Daniels J, Hummelshoj L, Cox E, Cooper KG. Surgical removal of superficial peritoneal endometriosis for managing women with chronic pelvic pain: time for a rethink? *BJOG* 2019;**126**:1414–1416.
- Howick J, Doshi P. On the ethical requirement to inform patients about potential treatment benefits. *BMJ* 2023;**381**:1233.
- Hunter DJ. Oral contraceptives and the small increased risk of breast cancer. *N Engl J Med* 2017;**377**:2276–2277.
- Iversen L, Fielding S, Lidegaard Ø, Mørch LS, Skovlund CW, Hannafor PC. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study. *BMJ* 2018;**362**:k3609.
- Iversen ML, Seyer-Hansen M, Forman A. Does surgery for deep infiltrating bowel endometriosis improve fertility? A systematic review. *Acta Obstet Gynecol Scand* 2017a;**96**:688–693.
- Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannafor PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. *Am J Obstet Gynecol* 2017b;**216**:580.e1–580.e9.
- Jensen JT, Schlaff W, Gordon K. Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence. *Fertil Steril* 2018;**110**:137–152.e1.
- Kadah S, Soh SE, Morin M, Schneider M, Ang WC, McPhate L, Frawley H. Are pelvic pain and increased pelvic floor muscle tone associated in women with persistent noncancer pelvic pain? A systematic review and meta-analysis. *J Sex Med* 2023;**20**:1206–1221.
- Kitawaki J, Kusuki I, Yamanaka K, Suganuma I. Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain. *Eur J Obstet Gynecol Reprod Biol* 2011;**157**:212–216.
- Klipping C, Duijkers I, Mawet M, Maillard C, Bastidas A, Jost M, Foidart JM. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. *Contraception* 2021;**103**:213–221.
- Kondo W, Bourdel N, Tamburro S, Cavoli D, Jardon K, Rabischong B, Botchorishvili R, Pouly J, Mage G, Canis M. Complications after surgery for deeply infiltrating pelvic endometriosis. *BJOG* 2011;**118**:292–298.
- Krabbenborg I, de Roos N, van der Grinten P, Nap A. Diet quality and perceived effects of dietary changes in Dutch endometriosis patients: an observational study. *Reprod Biomed Online* 2021;**43**:952–961.
- Lahoti A, Yu C, Brar PC, Dalgo A, Gourgari E, Harris R, Kamboj MK, Marks S, Nandagopal R, Page L et al. An endocrine perspective on menstrual suppression for adolescents: achieving good suppression while optimizing bone health. *J Pediatr Endocrinol Metab* 2021;**34**:1355–1369.
- Lamvu G, Carrillo J, Ouyang C, Rapkin A. Chronic pelvic pain in women: a review. *JAMA* 2021;**325**:2381–2391.
- Lamvu G, Carrillo J, Witzeman K, Alappattu M. Musculoskeletal considerations in female patients with chronic pelvic pain. *Semin Reprod Med* 2018;**36**:107–115.
- Latthe P, Mignini L, Gray R, Hills R, Khan K. Factors predisposing women to chronic pelvic pain: systematic review. *Bmj* 2006;**332**:749–755.
- Leonardi M, Gibbons T, Armour M, Wang R, Glanville E, Hodgson R, Cave AE, Ong J, Tong YYF, Jacobson TZ et al. When to do surgery and when not to do surgery for endometriosis: a systematic review and meta-analysis. *J Minim Invasive Gynecol* 2020a;**27**:390–407.e3.
- Leonardi M, Horne AW, Vincent K, Sinclair J, Sherman KA, Ciccio D, Condous G, Johnson NP, Armour M. Self-management strategies to consider to combat endometriosis symptoms during the COVID-19 pandemic. *Hum Reprod Open* 2020b;**2020**:hoaa028.
- Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: followup study, Denmark 2001–10. *BMJ* 2012;**344**:e2990.
- Liebermann C, Kohl Schwartz AS, Charpidou T, Geraedts K, Rauchfuss M, Wölfler M, von Orelli S, Häberlin F, Eberhard M, Imesch P et al. Maltreatment during childhood: a risk factor for the development of endometriosis? *Hum Reprod* 2018;**33**:1449–1458.
- Lopez LM, Grimes DA, Gallo MF, Stockton LL, Schulz KF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. *Cochrane Database Syst Rev* 2013;**2014**:CD004695.
- Lukas I, Kohl-Schwartz A, Geraedts K, Rauchfuss M, Wölfler MM, Häberlin F, von Orelli S, Eberhard M, Imthurn B, Imesch P et al. Satisfaction with medical support in women with endometriosis. *PLoS One* 2018;**13**:e0208023.
- MacGregor EA, Guillebaud J. The 7-day contraceptive hormone-free interval should be consigned to history. *BMJ Sex Reprod Health* 2018;**44**:214–220.

- Mackenzie SC, Stephen J, Williams L, Daniels J, Norrie J, Becker CM, Byrne D, Cheong Y, Clark TJ, Cooper KG *et al.* Effectiveness of laparoscopic removal of isolated superficial peritoneal endometriosis for the management of chronic pelvic pain in women (ESPrIT2): protocol for a multi-centre randomised controlled trial. *Trials* 2023;**24**:425.
- Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JL. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. *BMJ* 2012;**345**:e4944.
- Matsuzaki S, Houle C, Darcha C, Pouly JL, Mage G, Canis M. Analysis of risk factors for the removal of normal ovarian tissue during laparoscopic cystectomy for ovarian endometriosis. *Hum Reprod* 2009;**24**:1402–1406.
- Metzemaekers J, van den Akker-van Marle ME, Sampat J, Smeets MJGH, English J, Thijs E, Maas JWM, Willem Jansen F, Essers B. Treatment preferences for medication or surgery in patients with deep endometriosis and bowel involvement—a discrete choice experiment. *BJOG* 2022;**129**:1376–1385.
- Mitchell JB, Chetty S, Kathrada F. Progestins in the symptomatic management of endometriosis: a meta-analysis on their effectiveness and safety. *BMC Womens Health* 2022;**22**:526.
- Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. *Am J Obstet Gynecol* 2004;**191**:733–740.
- Morimont L, Jost M, Gaspard U, Foidart JM, Dogné JM, Douchfils J. Low thrombin generation in users of a contraceptive containing estetrol and drospirenone. *J Clin Endocrinol Metab* 2022;**108**:135–143.
- Mowers EL, Lim CS, Skinner B, Mahner N, Kamdar N, Morgan DM, As-Sanie S. Prevalence of endometriosis during abdominal or laparoscopic hysterectomy for chronic pelvic pain. *Obstet Gynecol* 2016;**127**:1045–1053.
- Muzii L, Di Tucci C, Achilli C, Di Donato V, Musella A, Palaia I, Panici PB. Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis. *Am J Obstet Gynecol* 2016;**214**:203–211.
- Muzii L, Di Tucci C, Galati G, Carbone F, Palaia I, Bogani G, Perniola G, Tomao F, Kontopantelis E, Di Donato V. The efficacy of dienogest in reducing disease and pain recurrence after endometriosis surgery: a systematic review and meta-analysis. *Reprod Sci* 2023;**30**:3135–3143.
- Mykita L, Cohen RA. *Characteristics of Adults Aged 18–64 Who Did Not Take Medication as Prescribed to Reduce Costs: United States, 2021*. National Center for Health Statistics, 2023. <https://www.cdc.gov/nchs/data/databriefs/db470.pdf> (30 June 2023, date last accessed).
- National Institute for Health and Care Excellence. *Endometriosis: Diagnosis and Management*. 2017a. <https://www.nice.org.uk/guidance/ng73/evidence/full-guideline-pdf-4550371315> (30 June 2023, date last accessed).
- National Institute for Health and Care Excellence. *Hormone Treatment for Endometriosis Symptoms—What Are My Options?* 2017b. <https://www.nice.org.uk/guidance/ng73/resources/patient-decision-aid-hormone-treatment-for-endometriosis-symptoms-what-are-my-options-pdf-4595573197> (30 June 2023, date last accessed).
- O'Hara R, Rowe H, Fisher J. Self-management factors associated with quality of life among women with endometriosis: a cross-sectional Australian survey. *Hum Reprod* 2021;**36**:647–655.
- Oedingen C, Scholz S, Razum O. Systematic review and meta-analysis of the association of combined oral contraceptives on the risk of venous thromboembolism: The role of the progestogen type and estrogen dose. *Thromb Res* 2018;**165**:68–78.
- Oppenheimer A, Verdun S, Perot M, Du Cheyron J, Panel P, Fauconnier A. Do high-dose progestins impair sexual function in women treated for endometriosis? A prospective observational longitudinal study. *Acta Obstet Gynecol Scand* 2021;**100**:850–859.
- Orr NL, Huang AJ, Liu YD, Noga H, Bedaiwy MA, Williams C, Allaire C, Yong PJ. Association of central sensitization inventory scores with pain outcomes after endometriosis surgery. *JAMA Netw Open* 2023;**6**:e230780.
- Pandya A. Adding cost-effectiveness to define low-value care. *JAMA* 2018;**319**:1977–1978.
- Panisch LS, Tam LM. The role of trauma and mental health in the treatment of chronic pelvic pain: a systematic review of the intervention literature. *Trauma Violence Abuse* 2020;**21**:1029–1043.
- Pastor Z, Holla K, Chmel R. The influence of combined oral contraceptives on female sexual desire: a systematic review. *Eur J Contracept Reprod Health Care* 2013;**18**:27–43.
- Pellicer A, Zupi E. Disclosure in scientific meetings: should we take any steps further? *Fertil Steril* 2016;**106**:1032.
- Plough T, Holm S. Conflict of interest disclosure and the polarisation of scientific communities. *J Med Ethics* 2015;**41**:356–358.
- Powell A. Choosing the right oral contraceptive pill for teens. *Pediatr Clin North Am* 2017;**64**:343–358.
- Ridgeway K, Montgomery ET, Smith K, Torjesen K, van der Straten A, Achilles SL, Griffin JB. Vaginal ring acceptability: a systematic review and meta-analysis of vaginal ring experiences from around the world. *Contraception* 2022;**106**:16–33.
- Roh YH, Kim S, Gong HS, Baek GH. Influence of centrally mediated symptoms on functional outcomes after carpal tunnel release. *Sci Rep* 2018;**8**:11134.
- Roman H, Bridoux V, Merlot B, Resch B, Chati R, Coget J, Forestier D, Tuech JJ. Risk of bowel fistula following surgical management of deep endometriosis of the rectosigmoid: a series of 1102 cases. *Hum Reprod* 2020;**35**:1601–1611.
- Roman H, Dennis T, Forestier D, François MO, Assenat V, Chanavaz-Lacheray I, Denost Q, Merlot B. Risk of rectovaginal fistula in women with excision of deep endometriosis requiring concomitant vaginal and rectal sutures, with or without preventive stoma: a before-and-after comparative study. *J Minim Invasive Gynecol* 2022;**30**:147–155.
- Royal College of General Practitioners. *Sexual and Contraceptive Health: Contraception Guidelines*. 2016. <https://elearning.rcgp.org.uk/mod/page/view.php?id=6961> (30 June 2023, date last accessed).
- Scerbo T, Colasurdo J, Dunn S, Unger J, Nijs J, Cook C. Measurement properties of the Central Sensitization Inventory: a systematic review. *Pain Pract* 2018;**18**:544–554.
- Schaffir J, Worly BL, Gur TL. Combined hormonal contraception and its effects on mood: a critical review. *Eur J Contracept Reprod Health Care* 2016;**21**:347–355.
- Schreurs AMF, Dancet EAF, Apers S, Kuchenbecker WKH, van de Ven PM, Maas JWM, Lambalk CB, Nelen WLD, van der Houwen LEE, Mijatovic V. The relationship between patient-centered care and quality of life in women with endometriosis. *Gynecol Obstet Invest* 2023;**88**:249–256.
- Schreurs AMF, Dancet EAF, Apers S, van Hoefen Wijsard M, Kuchenbecker WKH, van de Ven PM, Lambalk CB, Nelen WLD, van der Houwen LEE, Mijatovic V. A systematic review and secondary analysis of two studies identifying demographic and medical characteristics determining patient-centeredness in endometriosis care as experienced by patients. *Hum Reprod Open* 2020a;**2020**:hoaa041.
- Schreurs AMF, van Hoefen Wijsard M, Dancet EAF. Towards more patient centred endometriosis care: a cross sectional survey

- using the endocare questionnaire. *Hum Reprod Open* 2020b; **3**:hoaa029.
- Schreurs AMF, van Schaijk CI, De Bie B, Maas JWM, Lambalk C, van der Houwen LEE, Mijatovic V. Improving patient-centeredness in endometriosis care: a study protocol for a prospective study with a mixed-methods approach. *Gynecol Obstet Invest* 2021; **02186**:542–548.
- Seracchioli R, Mabrouk M, Manuzzi L, Vicenzi C, Frascà C, Elmakky A, Venturoli S. Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom-recurrence after conservative surgery for endometriosis. *Hum Reprod* 2009; **24**:2729–2735.
- Simpson G, Philip M, Lucky T, Ang C, Kathurusinghe S. A systematic review of the efficacy and availability of targeted treatments for central sensitization in women with endometriosis. *Clin J Pain* 2022; **38**:640–648.
- Song SY, Park M, Lee GW, Lee KH, Chang HK, Kwak SM, Yoo HJ. Efficacy of levonorgestrel releasing intrauterine system as a post-operative maintenance therapy of endometriosis: a meta-analysis. *Eur J Obstet Gynecol Reprod Biol* 2018; **231**:85–92.
- Sutton CJ, Ewen SP, Whitelaw N, Haines P. Prospective, randomized, double-blind, controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild, and moderate endometriosis. *Fertil Steril* 1994; **62**:696–700.
- Tepper NK, Dragoman MV, Gaffield ME, Curtis KM. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review. *Contraception* 2017; **95**:130–139.
- Thornton H. Communicating the benefits, harms, and risks of medical interventions: in journals; to patients and public. *Int J Surg* 2009; **7**:3–6.
- Thurnherr N, Burla L, Metzler JM, File B, Imesch P. Attitudes and perceptions of affected women towards endocrine endometriosis therapy: an international survey based on free-word association networks. *Hum Reprod* 2023;dead221. doi: [10.1093/humrep/dead221](https://doi.org/10.1093/humrep/dead221). Online ahead of print.
- Till SR, Schrepf A, Clauw DJ, Harte SE, Williams DA, As-Sanie S. Association between nociplastic pain and pain severity and impact in women with chronic pelvic pain. *J Pain* 2023; **24**:1406–1414.
- Vallee A, Ploteau S, Abo C, Stochino-Loi E, Moatassim-Drissa S, Marty N, Merlot B, Roman H. Surgery for deep endometriosis without involvement of digestive or urinary tracts: do not worry the patients!. *Fertil Steril* 2018; **109**:1079–1085.e1.
- Van Haaps A, Wijbers J, Schreurs A, Mijatovic V. A better quality of life could be achieved by applying the endometriosis diet: a cross-sectional study in Dutch endometriosis patients. *Reprod Biomed Online* 2023; **46**:623–630.
- Vercellini P, Bandini V, Buggio L, Barbara G, Berlanda N, Dridi D, Frattaruolo MP, Somigliana E. Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not? *Hum Reprod Open* 2023a; **2023**:hoad008.
- Vercellini P, Barbara G, Abbiati A, Somigliana E, Viganò P, Fedele L. Repetitive surgery for recurrent symptomatic endometriosis: what to do? *Eur J Obstet Gynecol Reprod Biol* 2009a; **146**:15–21.
- Vercellini P, Barbara G, Buggio L, Frattaruolo MP, Somigliana E, Fedele L. Effect of patient selection on estimate of reproductive success after surgery for rectovaginal endometriosis: literature review. *Reprod Biomed Online* 2012; **24**:389–395.
- Vercellini P, Barbara G, Somigliana E, Bianchi S, Abbiati A, Fedele L. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. *Fertil Steril* 2010; **93**:2150–2161.
- Vercellini P, Buggio L, Berlanda N, Barbara G, Somigliana E, Bosari S. Estrogen-progestins and progestins for the management of endometriosis. *Fertil Steril* 2016; **106**:1552–1571.e2.
- Vercellini P, Buggio L, Borghi A, Monti E, Gattei U, Frattaruolo MP. Medical treatment in the management of deep endometriosis infiltrating the proximal rectum and sigmoid colon: a comprehensive literature review. *Acta Obstet Gynecol Scand* 2018a; **97**:942–955.
- Vercellini P, Buggio L, Frattaruolo MP, Borghi A, Dridi D, Somigliana E. Medical treatment of endometriosis-related pain. *Best Pract Res Clin Obstet Gynaecol* 2018b; **51**:68–91.
- Vercellini P, Buggio L, Somigliana E. Role of medical therapy in the management of deep rectovaginal endometriosis. *Fertil Steril* 2017; **108**:913–930.
- Vercellini P, Donati A, Ottolini F, Frassinetti A, Fiorini J, Nebuloni V, Frattaruolo MP, Roberto A, Mosconi P, Somigliana E. A stepped-care approach to symptomatic endometriosis management: a participatory research initiative. *Fertil Steril* 2018c; **109**:1086–1096.
- Vercellini P, Esposito G, Santucci C, Parazzini F, La Vecchia C. Nomegestrol acetate for symptomatic endometriosis and meningioma risk: understandable statistics for decision-making. *Eur J Obstet Gynecol Reprod Biol* 2023b; **286**:149–150.
- Vercellini P, Facchin F, Buggio L, Barbara G, Berlanda N, Frattaruolo MP, Somigliana E. Management of endometriosis: toward value-based, cost-effective, affordable care. *J Obstet Gynaecol Can* 2018d; **40**:726–749.e10.
- Vercellini P, Frattaruolo MP, Buggio L. Toward minimally disruptive management of symptomatic endometriosis: reducing low-value care and the burden of treatment. *Expert Rev Pharmacoecon Outcomes Res* 2018e; **18**:1–4.
- Vercellini P, Giudice LC, Evers JL, Abrao MS. Reducing low-value care in endometriosis between limited evidence and unresolved issues: a proposal. *Hum Reprod* 2015; **30**:1996–2004.
- Vercellini P, Sergenti G, Buggio L, Frattaruolo MP, Dridi D, Berlanda N. Advances in the medical management of bowel endometriosis. *Best Pract Res Clin Obstet Gynaecol* 2021; **71**:78–99.
- Vercellini P, Somigliana E, Viganò P, De Matteis S, Barbara G, Fedele L. The effect of second-line surgery on reproductive performance of women with recurrent endometriosis: a systematic review. *Acta Obstet Gynecol Scand* 2009b; **88**:1074–1082.
- Vercellini P, Viganò P, Buggio L, Somigliana E. “We Can Work It Out:” the hundred years’ war between experts of surgical and medical treatment for symptomatic deep endometriosis. *J Minim Invasive Gynecol* 2018f; **25**:356–359.
- Vercellini P, Viganò P, Frattaruolo MP, Borghi A, Somigliana E. Bowel surgery as a fertility-enhancing procedure in patients with colorectal endometriosis: methodological, pathogenic and ethical issues. *Hum Reprod* 2018g; **33**:1205–1211.
- Vessey M, Yeates D. Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study. *Contraception* 2013; **88**:678–683.
- Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. *Contraception* 2010; **82**:221–229.
- Veth VB, van de Kar MM, Duffy JM, van Wely M, Mijatovic V, Maas JW. Gonadotropin-releasing hormone analogues for endometriosis. *Cochrane Database Syst Rev* 2023; **6**:CD014788.
- Whitaker LHR, Doust A, Stephen J, Norrie J, Cooper K, Daniels J, Hummelshoj L, Cox E, Beatty L, Chien P et al. Laparoscopic treatment of isolated superficial peritoneal endometriosis for managing chronic pelvic pain in women: study protocol for a randomised controlled feasibility trial (ESPrIT1). *Pilot Feasibility Stud* 2021; **7**:19.
- Wieggers HMG, Scheres LJJ, Tahir L, Hutten BA, Middeldorp S, Mijatovic V. Risk of venous thromboembolism in women with endometriosis. *Thromb Res* 2022; **217**:104–106.
- World Health Organisation. *Quality of Care: A Process for Making Strategic Choices in Health Systems*. Geneva, Switzerland: WHO Press, 2006.

- Worly BL, Gur TL, Schaffir J. The relationship between progestin hormonal contraception and depression: a systematic review. *Contraception* 2018;**97**:478–489.
- Xin L, Ma Y, Ye M, Chen L, Liu F, Hou Q. Efficacy and safety of oral gonadotropin-releasing hormone antagonists in moderate-to-severe endometriosis-associated pain: a systematic review and network meta-analysis. *Arch Gynecol Obstet* 2023; **308**:1047–1056.
- Yan H, Shi J, Li X, Dai Y, Wu Y, Zhang J, Gu Z, Zhang C, Leng J. Oral gonadotropin-releasing hormone antagonists for treating endometriosis-associated pain: a systematic review and network meta-analysis. *Fertil Steril* 2022;**118**:1102–1116.
- Yosef A, Allaire C, Williams C, Ahmed AG, Al-Hussaini T, Abdellah MS, Wong F, Lisonkova S, Yong PJ. Multifactorial contributors to the severity of chronic pelvic pain in women. *Am J Obstet Gynecol* 2016;**215**:760.e1–760.e14.
- Zakhari A, Delpero E, McKeown S, Tomlinson G, Bougie O, Murji A. Endometriosis recurrence following post-operative hormonal suppression: a systematic review and meta-analysis. *Hum Reprod Update* 2021;**27**:96–107.
- Zakhari A, Edwards D, Ryu M, Matelski JJ, Bougie O, Murji A. Dienogest and the risk of endometriosis recurrence following surgery: a systematic review and meta-analysis. *J Minim Invasive Gynecol* 2020;**27**:1503–1510.



QUALITY, INNOVATION, AND SERVICE—IT'S ALL AT THE CENTER OF EVERYTHING WE DO.

From developing assisted reproductive technologies that maximize performance, like the first ART media and cultures, to expertise that streamlines productivity, FUJIFILM Irvine Scientific brings together decades of industry expertise with a powerhouse of innovation, turning opportunities into realities. Together, we're working to support healthy futures—from retrieval to realization.

ALL IN FOR LIFE.
irvinesci.com/ALLIN